Naftifine hydrochloride - Generic Drug Details

What are the generic sources for naftifine hydrochloride and what is the scope of freedom to operate?

Naftifine hydrochloride is the generic ingredient in two branded drugs marketed by Amneal, Sun Pharma Canada, Xiromed, and Legacy Pharma, and is included in nine NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Naftifine hydrochloride has three patent family members in three countries.

There are seven drug master file entries for naftifine hydrochloride. Three suppliers are listed for this compound.

Summary for naftifine hydrochloride

International Patents:	3
US Patents:	6
Tradenames:	2
Applicants:	4
NDAs:	9
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	1,252
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for naftifine hydrochloride
What excipients (inactive ingredients) are in naftifine hydrochloride?	naftifine hydrochloride excipients list
DailyMed Link:	naftifine hydrochloride at DailyMed

Recent Clinical Trials for naftifine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GenZum Life Sciences LLC	Phase 3
Semler Research Center Pvt. Ltd.	Phase 3
Genzum Life Sciences	Phase 3

See all naftifine hydrochloride clinical trials

Pharmacology for naftifine hydrochloride

Drug Class

Allylamine Antifungal

Anatomical Therapeutic Chemical (ATC) Classes for naftifine hydrochloride

D01AE	Other antifungals for topical use
D01A	ANTIFUNGALS FOR TOPICAL USE
D01	ANTIFUNGALS FOR DERMATOLOGICAL USE
D	Dermatologicals

Paragraph IV (Patent) Challenges for NAFTIFINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAFTIN	Gel	naftifine hydrochloride	2%	204286	1	2015-02-04

US Patents and Regulatory Information for naftifine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Legacy Pharma	NAFTIN	naftifine hydrochloride	CREAM;TOPICAL	019599-001	Feb 29, 1988		DISCN	Yes	No
Legacy Pharma	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	019356-001	Jun 18, 1990		RX	Yes	Yes
Amneal	NAFTIFINE HYDROCHLORIDE	naftifine hydrochloride	CREAM;TOPICAL	206960-001	Apr 10, 2017		DISCN	No	No

Expired US Patents for naftifine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Legacy Pharma	NAFTIN	naftifine hydrochloride	CREAM;TOPICAL	019599-001	Feb 29, 1988
Legacy Pharma	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	019356-001	Jun 18, 1990
Legacy Pharma	NAFTIN	naftifine hydrochloride	GEL;TOPICAL	019356-001	Jun 18, 1990

International Patents for naftifine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Australia	2014212201	Topical compositions and methods for making and using same
Canada	2899725	COMPOSITIONS TOPIQUES ET PROCEDES DE PREPARATION ET D'UTILISATION CORRESPONDANTS (TOPICAL COMPOSITIONS AND METHODS FOR MAKING AND USING SAME)
World Intellectual Property Organization (WIPO)	2014121048

Last updated: June 28, 2026

Naftifine Hydrochloride Market Dynamics and Financial Trajectory (2026 View)

Naftifine hydrochloride is a topical antifungal with market performance driven by (1) stable prevalence of dermatophyte and superficial fungal infections in target geographies, (2) low-cost generic competition, and (3) regulatory and reimbursement depth for over-the-counter (OTC) versus prescription access. Financial trajectory is typically characterized by modest, mature-lifecycle growth where volume is resilient but pricing power is limited, with revenue increasingly concentrated in branded-to-generic transitions and channel-specific formulations (cream/gel/solution).

However, a complete, accurate financial trajectory (revenue, CAGR, margins, segment shares by geography/formulation, and branded vs generic shares) cannot be produced from the provided prompt alone.

How big is the naftifine hydrochloride market and what drives demand?

Answer: Demand is driven by persistent incidence of superficial mycoses (tinea corporis/cruris/pedis, pityriasis versicolor, cutaneous candidiasis) and by access channel mix (OTC retail vs prescription). Growth is mostly volume-led rather than price-led in most markets after generic entry.

What infection indications support recurring use

• Dermatophyte infections treated with topical allylamine-class antifungals
• Tinea pedis with chronicity and recurrence dynamics that favor ongoing retail procurement
• Onychomycosis is more often managed with other regimens, but topical antifungals can still contribute in early-stage or adjunct settings depending on local labeling

What changes in healthcare behavior alter sales

• OTC liberalization increases retail capture and reduces prescription drag
• Stewardship policies that limit broad antifungal prescribing can shift volume toward self-diagnosed retail use
• Increased dermatology and primary care consultation for skin complaints can lift prescription throughput in some markets

Key market micro-drivers

• Price erosion after generic launches
• Formulation preferences (cream vs gel vs solution) and skin tolerability perceptions
• Seasonal patterns for tinea-related visits and OTC conversion (often higher in warmer months)

What is the pricing power outlook for naftifine hydrochloride as generics expand?

Answer: Pricing power is usually weak after initial branded uptake because topical antifungals face near-immediate generic substitutability, especially across standard dosage forms.

Why topical antifungals compress margins

• Active ingredient substitution at the pharmacy counter is common once multiple ANDA-like equivalents exist
• Payors and formularies often treat topical antifungals as therapeutically interchangeable within class and indication scope
• Retail channel switching reduces brand differentiation once price gaps widen

How channel mix changes financial trajectory

• Prescription-heavy markets tend to see slower price decay but sustained volume if brand is preferred by formularies
• OTC-heavy markets can show faster share loss after generic pricing undercuts, while total market volume can remain stable

What drives revenue growth versus share loss for naftifine hydrochloride over time?

Answer: Revenue growth is typically modest once competition is established; share loss offsets volume stability and drives net pricing pressure. Net growth is often positive only where population growth, dermatology access expansion, or formulation expansion occurs.

Typical lifecycle pattern

1. Early phase: branded differentiation, clinician familiarity, limited competition
2. Transition phase: generic penetration increases price competition
3. Mature phase: revenue becomes mostly resilient but margin compresses; growth depends on channel shifts and formulation mix

Where upside can still come from

• Higher conversion to preferred formulations (e.g., gel for oozing/occluded areas in local practice)
• Geographic expansion into markets with later generic introduction
• Adjunct use expansions within skin-care and dermatology workflows

How does regulatory status and exclusivity affect market entry and competition?

Answer: Topical small-molecule antifungals usually have limited barriers once compound and formulation patents expire, with generic entry accelerating competition.

What typically governs market exclusivity in practice

• Compound patent expiry (active ingredient)
• Formulation and packaging patents (cream/gel/solution, preservative systems, concentrations)
• Regulatory data exclusivity and any pediatric or supplementary protection mechanisms in specific jurisdictions

What changes generic availability fastest

• Clearance of marketing approvals for therapeutically equivalent products
• Evidence requirements that support bioequivalence or comparable performance for topical dosage forms

Which dosage forms and formulations matter most for sales trajectory?

Answer: Market outcomes depend on how consumers and clinicians choose among cream, gel, and solution, and how product usability maps to adherence and skin tolerability.

Formulation-level considerations

• Cream: broad use, perceived skin comfort
• Gel: fast drying, perceived suitability for hair-bearing or intertriginous areas in some practice settings
• Solution: often preferred for scalp or areas where drying/coverage matters

What formulation can shift

• High-frequency relapses increase repurchase cycles
• Local labeling that supports specific indications can materially affect substitution patterns

How does naftifine hydrochloride compare with competing topical antifungals commercially?

Answer: Commercial performance tends to track relative affordability and clinician/patient familiarity against other topical antifungals (allylamines and azoles). The main competitive levers are price, availability, and tolerability.

Competitive set (typical class substitutes)

• Other allylamines (e.g., terbinafine topical)
• Azoles (e.g., clotrimazole, ketoconazole topical in various markets)
• Polyenes or other topical options where regionally prevalent

Where pricing and channel execution decide outcomes

• If a competitor has lower price per treatment cycle, market share usually follows in retail channels
• Prescription formularies often drive share stability for whichever brand has formulary positions

What financial trajectory is typical for mature, generic-exposed topical antifungals like naftifine?

Answer: Mature topical antifungal brands generally show:

• Flattening unit growth
• Declining net price
• Stable-to-slightly declining margins
• Revenue that is either flat or modestly positive depending on mix shifts and geography

Revenue line items that usually deteriorate

• Gross margin: compression from generic price competition and promotional intensity
• Net sales: stable volume offset by lower realized prices
• Marketing spend efficiency: ROAS declines as category is commoditized

What generic entry risks exist for naftifine hydrochloride products?

Answer: Generic entry risk is typically high for any branded topical product that relies primarily on compound exclusivity, because topical antifungal actives have strong substitutability.

Common entry accelerants

• Multiple existing approvals by region for the same active ingredient and dosage form
• Local manufacturing capability that reduces lead times
• Low formulation complexity relative to biologics and many high-barrier devices

How does manufacturing and supply chain risk affect market performance?

Answer: In mature generic markets, supply chain disruptions can temporarily raise price and stabilize revenue, but sustained allocation issues usually shift demand toward substitute actives.

Operational risk patterns

• API sourcing concentration can create short-term shortages
• Contract manufacturing lead times can affect launch continuity for relabeled products
• Quality excursions can trigger tender de-listing in some public procurement systems

What does the competitive landscape imply for profitability and long-term cash flows?

Answer: The landscape usually supports stable category volume but limited long-run margin expansion. Cash flows are typically supported by ongoing repurchase demand rather than premium pricing.

Profit drivers

• Lowest-cost supply chain and scale
• Fast remediation of formulation defects to avoid regulatory actions
• Distribution reach in OTC and in tender-led prescription markets

Profit headwinds

• Continued price erosion
• Increased promotional and trade spending
• Patent-for-service settlements in some regions for brand originators, though topical assets often transition without long litigation cascades in mature periods

Key Takeaways

• Naftifine hydrochloride is a mature topical antifungal where volume resilience tends to beat price growth once generics are established.
• Financial trajectory in most markets is driven by channel mix (OTC vs prescription), dosage-form preferences (cream/gel/solution), and pricing erosion after generic entry.
• Long-term profitability is typically constrained by therapeutic substitutability and commodity-like competition, making realized price and supply economics the dominant levers.

FAQs

1. Is naftifine hydrochloride primarily OTC or prescription in major markets, and how does that change demand?
2. Which dosage form (cream vs gel vs solution) typically shows the best adherence and repeat purchase behavior?
3. How do price-per-treatment-cycle comparisons usually play out between naftifine and azole/allylamine topical competitors?
4. What manufacturing or regulatory events most often cause temporary sales spikes or sustained de-listing for topical antifungals?
5. How do public procurement and tender frameworks affect the profitability of naftifine products versus private retail channels?

References

1. No sources were provided in the prompt; no citations can be generated without source material.